PT1007088E - Vector de adenovírus porcino recombinante - Google Patents
Vector de adenovírus porcino recombinante Download PDFInfo
- Publication number
- PT1007088E PT1007088E PT98938527T PT98938527T PT1007088E PT 1007088 E PT1007088 E PT 1007088E PT 98938527 T PT98938527 T PT 98938527T PT 98938527 T PT98938527 T PT 98938527T PT 1007088 E PT1007088 E PT 1007088E
- Authority
- PT
- Portugal
- Prior art keywords
- pav
- recombinant
- porcine
- sequence
- vector
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract description 66
- 241000188845 Porcine adenovirus Species 0.000 title claims abstract description 54
- 241000282887 Suidae Species 0.000 claims abstract description 44
- 229960005486 vaccine Drugs 0.000 claims abstract description 43
- 239000002773 nucleotide Substances 0.000 claims abstract description 37
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 37
- 238000000034 method Methods 0.000 claims abstract description 24
- 201000010099 disease Diseases 0.000 claims abstract description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 23
- 230000000890 antigenic effect Effects 0.000 claims abstract description 21
- 238000004519 manufacturing process Methods 0.000 claims abstract description 14
- 238000002360 preparation method Methods 0.000 claims abstract description 7
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 claims abstract description 4
- 238000002255 vaccination Methods 0.000 claims description 46
- 241000282898 Sus scrofa Species 0.000 claims description 30
- 241000700605 Viruses Species 0.000 claims description 29
- 208000015181 infectious disease Diseases 0.000 claims description 28
- 238000003780 insertion Methods 0.000 claims description 19
- 230000037431 insertion Effects 0.000 claims description 19
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 17
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 17
- 210000000265 leukocyte Anatomy 0.000 claims description 17
- 239000012634 fragment Substances 0.000 claims description 15
- 230000002434 immunopotentiative effect Effects 0.000 claims description 13
- 229920001184 polypeptide Polymers 0.000 claims description 13
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 210000004698 lymphocyte Anatomy 0.000 claims description 12
- 101710170453 Glycoprotein 55 Proteins 0.000 claims description 10
- 230000002458 infectious effect Effects 0.000 claims description 8
- 108091008146 restriction endonucleases Proteins 0.000 claims description 8
- 238000011144 upstream manufacturing Methods 0.000 claims description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 7
- 108010008038 Synthetic Vaccines Proteins 0.000 claims description 7
- 229940124551 recombinant vaccine Drugs 0.000 claims description 7
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 230000024932 T cell mediated immunity Effects 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 238000005457 optimization Methods 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 206010008631 Cholera Diseases 0.000 claims description 4
- 102000000646 Interleukin-3 Human genes 0.000 claims description 4
- 108010002386 Interleukin-3 Proteins 0.000 claims description 4
- 102000004388 Interleukin-4 Human genes 0.000 claims description 4
- 108090000978 Interleukin-4 Proteins 0.000 claims description 4
- 229940076264 interleukin-3 Drugs 0.000 claims description 4
- 229940028885 interleukin-4 Drugs 0.000 claims description 4
- 208000009305 pseudorabies Diseases 0.000 claims description 4
- 210000002845 virion Anatomy 0.000 claims description 4
- 241000711573 Coronaviridae Species 0.000 claims description 3
- 238000002965 ELISA Methods 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 241000702619 Porcine parvovirus Species 0.000 claims description 3
- 241000702665 Porcine rotavirus Species 0.000 claims description 3
- 101710172711 Structural protein Proteins 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 3
- 210000003714 granulocyte Anatomy 0.000 claims description 3
- 239000012678 infectious agent Substances 0.000 claims description 3
- 230000004936 stimulating effect Effects 0.000 claims description 3
- 102000008070 Interferon-gamma Human genes 0.000 claims description 2
- 108010074328 Interferon-gamma Proteins 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 241001492389 Porcine adenovirus 3 Species 0.000 claims description 2
- 239000000443 aerosol Substances 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 108700014844 flt3 ligand Proteins 0.000 claims description 2
- 239000002054 inoculum Substances 0.000 claims description 2
- 229960003130 interferon gamma Drugs 0.000 claims description 2
- 208000023504 respiratory system disease Diseases 0.000 claims description 2
- 239000007921 spray Substances 0.000 claims description 2
- LXWYCLOUQZZDBD-LIYNQYRNSA-N csfv Chemical compound C([C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)[C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 LXWYCLOUQZZDBD-LIYNQYRNSA-N 0.000 claims 3
- 102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims 1
- 101000746367 Homo sapiens Granulocyte colony-stimulating factor Proteins 0.000 claims 1
- 102000003960 Ligases Human genes 0.000 claims 1
- 108090000364 Ligases Proteins 0.000 claims 1
- 241001332277 Porcine parainfluenza virus Species 0.000 claims 1
- 241001135989 Porcine reproductive and respiratory syndrome virus Species 0.000 claims 1
- 238000010790 dilution Methods 0.000 claims 1
- 239000012895 dilution Substances 0.000 claims 1
- 208000028774 intestinal disease Diseases 0.000 claims 1
- 238000002156 mixing Methods 0.000 claims 1
- 241000710777 Classical swine fever virus Species 0.000 abstract description 15
- 108020004414 DNA Proteins 0.000 description 29
- 108090000623 proteins and genes Proteins 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 15
- 241000701161 unidentified adenovirus Species 0.000 description 13
- 210000003292 kidney cell Anatomy 0.000 description 11
- 238000010276 construction Methods 0.000 description 9
- 230000008859 change Effects 0.000 description 8
- 238000012217 deletion Methods 0.000 description 8
- 230000037430 deletion Effects 0.000 description 8
- 238000003752 polymerase chain reaction Methods 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 239000000427 antigen Substances 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 6
- 230000028993 immune response Effects 0.000 description 6
- 230000036039 immunity Effects 0.000 description 6
- 206010012735 Diarrhoea Diseases 0.000 description 5
- 238000012512 characterization method Methods 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 230000006801 homologous recombination Effects 0.000 description 5
- 238000002744 homologous recombination Methods 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 230000008488 polyadenylation Effects 0.000 description 5
- 230000000241 respiratory effect Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 4
- 241000598171 Human adenovirus sp. Species 0.000 description 4
- 108091034117 Oligonucleotide Proteins 0.000 description 4
- 238000010367 cloning Methods 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 238000009396 hybridization Methods 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 230000003472 neutralizing effect Effects 0.000 description 4
- 230000007918 pathogenicity Effects 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 3
- 108090000695 Cytokines Proteins 0.000 description 3
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 244000144980 herd Species 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007619 statistical method Methods 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 108010062580 Concanavalin A Proteins 0.000 description 2
- 230000007023 DNA restriction-modification system Effects 0.000 description 2
- 238000001712 DNA sequencing Methods 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 2
- 206010022678 Intestinal infections Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 230000006052 T cell proliferation Effects 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108010006785 Taq Polymerase Proteins 0.000 description 2
- 230000002238 attenuated effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 239000004020 conductor Substances 0.000 description 2
- HAAZLUGHYHWQIW-KVQBGUIXSA-N dGTP Chemical group C1=NC=2C(=O)NC(N)=NC=2N1[C@H]1C[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O1 HAAZLUGHYHWQIW-KVQBGUIXSA-N 0.000 description 2
- 238000001962 electrophoresis Methods 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000007952 growth promoter Substances 0.000 description 2
- 238000010166 immunofluorescence Methods 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 231100000636 lethal dose Toxicity 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 238000012163 sequencing technique Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000000638 stimulation Effects 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 239000013603 viral vector Substances 0.000 description 2
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- 241000701386 African swine fever virus Species 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108010037936 CCCGGG-specific type II deoxyribonucleases Proteins 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 101900173079 Classical swine fever virus Envelope glycoprotein E2 Proteins 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 108010008286 DNA nucleotidylexotransferase Proteins 0.000 description 1
- 102100033215 DNA nucleotidylexotransferase Human genes 0.000 description 1
- 230000003682 DNA packaging effect Effects 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 1
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 206010017964 Gastrointestinal infection Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 101000807236 Human cytomegalovirus (strain AD169) Membrane glycoprotein US3 Proteins 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 241000710842 Japanese encephalitis virus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000701244 Mastadenovirus Species 0.000 description 1
- NTIZESTWPVYFNL-UHFFFAOYSA-N Methyl isobutyl ketone Chemical compound CC(C)CC(C)=O NTIZESTWPVYFNL-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000008071 Parvoviridae Infections Diseases 0.000 description 1
- 101710193132 Pre-hexon-linking protein VIII Proteins 0.000 description 1
- 241000125945 Protoparvovirus Species 0.000 description 1
- 208000035415 Reinfection Diseases 0.000 description 1
- 108091081062 Repeated sequence (DNA) Proteins 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 241000702670 Rotavirus Species 0.000 description 1
- 206010067470 Rotavirus infection Diseases 0.000 description 1
- 108700026226 TATA Box Proteins 0.000 description 1
- 206010058874 Viraemia Diseases 0.000 description 1
- 101710097943 Viral-enhancing factor Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 229940021704 adenovirus vaccine Drugs 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000004727 amygdala Anatomy 0.000 description 1
- 230000005875 antibody response Effects 0.000 description 1
- 241000701792 avian adenovirus Species 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 210000003022 colostrum Anatomy 0.000 description 1
- 235000021277 colostrum Nutrition 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000000609 ganglia Anatomy 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000000091 immunopotentiator Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 229940031551 inactivated vaccine Drugs 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 208000010753 nasal discharge Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 231100000915 pathological change Toxicity 0.000 description 1
- 230000036285 pathological change Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 235000015277 pork Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108010058147 pseudorabies virus glycoprotein D Proteins 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 208000012153 swine disease Diseases 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 229940126580 vector vaccine Drugs 0.000 description 1
- 239000005723 virus inoculator Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/235—Adenoviridae
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/53—Colony-stimulating factor [CSF]
- C07K14/535—Granulocyte CSF; Granulocyte-macrophage CSF
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
- C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPO8560A AUPO856097A0 (en) | 1997-08-14 | 1997-08-14 | Vector |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PT1007088E true PT1007088E (pt) | 2007-05-31 |
Family
ID=3802849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PT98938527T PT1007088E (pt) | 1997-08-14 | 1998-08-14 | Vector de adenovírus porcino recombinante |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US7323177B1 (enExample) |
| EP (2) | EP1007088B1 (enExample) |
| JP (2) | JP4365023B2 (enExample) |
| KR (1) | KR100746524B1 (enExample) |
| CN (1) | CN100366292C (enExample) |
| AT (1) | ATE357250T1 (enExample) |
| AU (2) | AUPO856097A0 (enExample) |
| BR (1) | BR9811184A (enExample) |
| CY (1) | CY1106565T1 (enExample) |
| DE (1) | DE69837390T2 (enExample) |
| DK (1) | DK1007088T3 (enExample) |
| ES (1) | ES2283068T3 (enExample) |
| ID (1) | ID24174A (enExample) |
| MX (1) | MXPA00001562A (enExample) |
| NZ (1) | NZ503039A (enExample) |
| PT (1) | PT1007088E (enExample) |
| WO (1) | WO1999008706A1 (enExample) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AUPO856097A0 (en) | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| US6492343B1 (en) | 1998-04-15 | 2002-12-10 | University Of Saskatchewan | Porcine adenovirus type 3 genome |
| FR2789695B1 (fr) * | 1999-02-11 | 2003-03-07 | Merial Sas | Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs |
| FR2804028B1 (fr) * | 2000-01-21 | 2004-06-04 | Merial Sas | Vaccins adn ameliores pour animaux de rente |
| CA2413265A1 (en) * | 2000-05-03 | 2001-11-08 | University Of Guelph | Porcine adenovirus type 5 vector and vaccine |
| WO2002031168A2 (en) * | 2000-10-10 | 2002-04-18 | Genstar Therapeutics | Minimal adenoviral vector and recombinant vaccines based thereon |
| US6794163B2 (en) | 2001-03-27 | 2004-09-21 | University Of Saskatchewan | Methods to culture circovirus |
| WO2003013598A2 (en) * | 2001-08-09 | 2003-02-20 | Lam Dominic M K | Novel vaccine compositions and methods of vaccine preparation for veterinary and human diseases |
| AU2002327614B2 (en) | 2001-09-06 | 2007-12-06 | Alphavax, Inc. | Alphavirus replicon vector systems |
| JP3949520B2 (ja) * | 2001-09-20 | 2007-07-25 | 独立行政法人科学技術振興機構 | レギュカルチン過剰発現モデル動物 |
| US7569217B2 (en) | 2001-09-24 | 2009-08-04 | University Of Saskatchewan | Porcine adenovirus E1 and E4 regions |
| KR20030054139A (ko) * | 2001-12-24 | 2003-07-02 | 학교법인 건국대학교 | 돼지 오제스키병 바이러스의 ｇＤ 유전자를 포함하는재조합 발현 벡터 및 이를 이용한 ＤＮＡ 백신 |
| US7906311B2 (en) | 2002-03-20 | 2011-03-15 | Merial Limited | Cotton rat lung cells for virus culture |
| ES2618309T3 (es) | 2002-12-13 | 2017-06-21 | Alphavax, Inc. | Partículas de replicón de alfavirus multi-antigénico y métodos |
| DK2290054T3 (en) | 2002-12-13 | 2017-07-03 | Alphavax Inc | Alpha virus particles and processes for their preparation |
| JP5016305B2 (ja) | 2003-03-20 | 2012-09-05 | アルファヴァックス，インコーポレイテッド | 改良されたアルファウイルスレプリコンおよびヘルパー構築物 |
| EP1651666B1 (en) | 2003-07-11 | 2009-05-27 | Alphavax, Inc. | Alphavirus-based cytomegalovirus vaccines |
| EP1751289B1 (en) | 2004-05-18 | 2009-01-14 | Alphavax, Inc. | Tc-83-derived alphavirus vectors, particles and methods |
| UA95458C2 (ru) * | 2005-09-09 | 2011-08-10 | Интервет Интернешонал Б.В. | Вакцина против pcv-2 у mda-положительных поросят |
| AU2007278887A1 (en) * | 2006-07-28 | 2008-01-31 | Commonwealth Scientific And Industrial Research Organisation | Methods and compositions for increasing tissue tropism of recombinant adenoviral vectors |
| PL2183368T3 (pl) | 2007-06-21 | 2016-12-30 | Kasety bez promotora do ekspresji alfawirusowych białek strukturalnych | |
| US20100150959A1 (en) * | 2008-12-15 | 2010-06-17 | Vectogen Pty Ltd. | PCV 2-Based Methods and Compositions for the Treatment of Pigs |
| US20110135688A1 (en) * | 2009-12-04 | 2011-06-09 | Michael Sheppard | Methods and Compositions for Increasing Titer of Recombinant Porcine Adenovirus-3 Vectors |
| CA2872789C (en) | 2012-05-17 | 2019-09-03 | Zoetis Llc | Effective vaccination against porcine reproductive and respiratory syndrome (prrs) virus prior to weaning |
| AU2015218769B2 (en) * | 2014-02-20 | 2020-09-17 | Vaxart, Inc. | Formulations for small intestinal delivery |
| EA201792512A1 (ru) | 2015-06-12 | 2018-06-29 | Вэксарт, Инк. | Составы для доставки антигенов респираторного синтициального вируса и норовируса в тонкий кишечник |
| CN110072547B (zh) | 2016-12-14 | 2024-04-30 | 硕腾服务有限责任公司 | 断奶前对抗欧洲猪繁殖与呼吸综合征(prrs)病毒株的有效疫苗接种 |
| CN110904127B (zh) * | 2018-09-18 | 2024-09-20 | 瓦赫宁恩研究基金会 | 非洲猪瘟病毒疫苗 |
| EP4277933A4 (en) | 2021-01-14 | 2024-12-11 | Senti Biosciences, Inc. | SECRETABLE PAYLOAD REGULATION |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4320068C1 (de) | 1993-06-17 | 1994-12-15 | Audi Ag | Verfahren und Vorrichtung zur Reparatur von Fahrzeugkarosserien aus Leichtmetallteilen |
| FI951138L (fi) * | 1993-07-13 | 1995-04-13 | Rhone Poulenc Rorer Sa | Puuttellisia adenovirusvektoreita ja niiden käyttö geeniterapiassa |
| BR9508224A (pt) | 1994-07-14 | 1997-10-28 | Union Camp Patent Holding | Processo tendo seletividade aumentada para alvejamento de polpa lignocelulósica alvejada |
| FR2725213B1 (fr) | 1994-10-04 | 1996-11-08 | Rhone Poulenc Rorer Sa | Vecteurs viraux et utilisation en therapie genique |
| ES2105984B1 (es) * | 1995-11-30 | 1998-04-16 | Iberica Cyanamid | Adenovirus recombinantes que expresan antigenos del virus de la gastroenteritis porcina transmisible (vgpt) y su empleo en la formacion de vacunas. |
| AUPO856097A0 (en) * | 1997-08-14 | 1997-09-04 | Commonwealth Scientific And Industrial Research Organisation | Vector |
| US6492343B1 (en) | 1998-04-15 | 2002-12-10 | University Of Saskatchewan | Porcine adenovirus type 3 genome |
-
1997
- 1997-08-14 AU AUPO8560A patent/AUPO856097A0/en not_active Abandoned
-
1998
- 1998-08-14 KR KR1020007001486A patent/KR100746524B1/ko not_active Expired - Fee Related
- 1998-08-14 DE DE69837390T patent/DE69837390T2/de not_active Expired - Lifetime
- 1998-08-14 EP EP98938527A patent/EP1007088B1/en not_active Expired - Lifetime
- 1998-08-14 US US09/485,512 patent/US7323177B1/en not_active Expired - Fee Related
- 1998-08-14 ES ES98938527T patent/ES2283068T3/es not_active Expired - Lifetime
- 1998-08-14 CN CNB98809116XA patent/CN100366292C/zh not_active Expired - Fee Related
- 1998-08-14 ID IDW20000491A patent/ID24174A/id unknown
- 1998-08-14 WO PCT/AU1998/000648 patent/WO1999008706A1/en not_active Ceased
- 1998-08-14 BR BR9811184-1A patent/BR9811184A/pt not_active IP Right Cessation
- 1998-08-14 NZ NZ503039A patent/NZ503039A/xx not_active IP Right Cessation
- 1998-08-14 PT PT98938527T patent/PT1007088E/pt unknown
- 1998-08-14 DK DK98938527T patent/DK1007088T3/da active
- 1998-08-14 AT AT98938527T patent/ATE357250T1/de active
- 1998-08-14 MX MXPA00001562A patent/MXPA00001562A/es active IP Right Grant
- 1998-08-14 EP EP07005454A patent/EP1825863A1/en not_active Withdrawn
- 1998-08-14 JP JP2000509443A patent/JP4365023B2/ja not_active Expired - Fee Related
-
2006
- 2006-03-22 US US11/387,026 patent/US7473428B2/en not_active Expired - Fee Related
-
2007
- 2007-05-07 CY CY20071100603T patent/CY1106565T1/el unknown
-
2008
- 2008-08-22 US US12/197,056 patent/US7785602B2/en not_active Expired - Fee Related
-
2009
- 2009-07-01 JP JP2009156467A patent/JP2009213495A/ja active Pending
-
2011
- 2011-09-09 AU AU2011224111A patent/AU2011224111A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| US20090226485A1 (en) | 2009-09-10 |
| KR100746524B1 (ko) | 2007-08-07 |
| DE69837390D1 (de) | 2007-05-03 |
| ES2283068T3 (es) | 2007-10-16 |
| EP1007088A4 (en) | 2003-01-08 |
| MXPA00001562A (es) | 2004-10-14 |
| US20060263387A1 (en) | 2006-11-23 |
| ID24174A (id) | 2000-07-13 |
| EP1007088B1 (en) | 2007-03-21 |
| KR20010022882A (ko) | 2001-03-26 |
| EP1007088A1 (en) | 2000-06-14 |
| ATE357250T1 (de) | 2007-04-15 |
| NZ503039A (en) | 2002-09-27 |
| DE69837390T2 (de) | 2007-08-23 |
| JP2001514871A (ja) | 2001-09-18 |
| AUPO856097A0 (en) | 1997-09-04 |
| US7785602B2 (en) | 2010-08-31 |
| WO1999008706A8 (en) | 2000-08-10 |
| JP2009213495A (ja) | 2009-09-24 |
| CN1275084A (zh) | 2000-11-29 |
| DK1007088T3 (da) | 2007-06-04 |
| CY1106565T1 (el) | 2012-01-25 |
| AU2011224111A1 (en) | 2011-10-13 |
| EP1825863A1 (en) | 2007-08-29 |
| WO1999008706A1 (en) | 1999-02-25 |
| US7473428B2 (en) | 2009-01-06 |
| US7323177B1 (en) | 2008-01-29 |
| CN100366292C (zh) | 2008-02-06 |
| HK1032755A1 (zh) | 2001-08-03 |
| BR9811184A (pt) | 2001-12-26 |
| JP4365023B2 (ja) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US7785602B2 (en) | Recombinant porcine adenovirus vector | |
| AU633663B2 (en) | Recombinant herpesvirus of turkeys and live vector vaccines derived thereof | |
| TW201026850A (en) | PCV 2-based methods and compositions for the treatment of pigs | |
| JPH08500969A (ja) | 七面鳥の組換えヘルペスウイルス及びそれらの使用 | |
| JP3606870B2 (ja) | 組換えトリアデノウイルスベクター | |
| CA2413265A1 (en) | Porcine adenovirus type 5 vector and vaccine | |
| JPH10506018A (ja) | 不活化ＩＶａ２遺伝子を有する欠陥組換えアデノウィルス | |
| JP2002508661A (ja) | ウシアデノウイルスタイプ３ゲノム | |
| US6296852B1 (en) | Recombinant avian adenovirus vector | |
| CN103667198B (zh) | 表达分泌型鸭坦布苏病毒e蛋白的重组鸭病毒性肠炎病毒疫苗的构建和应用 | |
| AU757683B2 (en) | Recombinant porcine adenovirus vector | |
| AU2001280006B2 (en) | Adenovirus vectors comprising introns | |
| JPH09505726A (ja) | 組換え感染性喉頭気管炎ウイルス及びそれらの使用 | |
| CN101454442A (zh) | 嵌合体prrsv的构建，组合物及疫苗的制备 | |
| HUP0103871A2 (hu) | Rekombináns CELO-vírus és CELO vírus DNS | |
| HK1032755B (en) | Recombinant porcine adenovirus vector | |
| TW201208697A (en) | Porcine adenovirus 3-based PRRSV vaccines | |
| AU2001280006A1 (en) | Adenovirus vectors comprising introns |